Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

1. Pliant Therapeutics discontinued the BEACON-IPF Phase 2b trial for bexotegrast. 2. Trial discontinuation followed DSMB recommendations due to adverse events imbalance. 3. Despite this, early efficacy on forced vital capacity (FVC) was observed. 4. Pliant plans to analyze trial data for future bexotegrast studies. 5. PLRX stock fell 51%, pricing at $1.69 after the announcement.